PRIMARY OBJECTIVE:~To determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing).~SECONDARY OBJECTIVES:~To determine overall survival and progression free survival.~To determine time to progression.~To determine objective response rate at one year.~To determine time to and duration of tumor response.~To assess safety profile including a dedicated cardiovascular management (home-blood pressure monitoring, ECG and echocardiography).~EXPLORATORY OBJECTIVES:~-Identification of predictors of response as well as surrogate markers of overall survival is anticipated
The FIRSTMAPPP study is a randomized, double-blind, phase II, international, multicenter study which aims to determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing).